IHMO
LANI can replace TAMIFLU for ROCHE as by then TAMIFLU's patent would have ran out.
I think the success of new products depends on the direction of management of the big PHARMAs. If relenza was pushed by ROCHE in the first place, perhaps Relenza would be sitting much better in the market. If ROCHE makes a deal with BIOTA/SANKYO, it surely will be better than with GSK, at least it does not have GSK's pre-pandemic vaccine to content with for GSK's internal marketing budget.
- Forums
- ASX - By Stock
- BTA
- upgrade from abn amro
upgrade from abn amro, page-6
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
NEWS
Antler Copper Project hits major permitting milestone – air quality permit advances to final review
CC9
Chariot Corporation (ASX:CC9) refines Black Mountain strategy, launching Pilot Mine to seize U.S. lithium opportunity